Precisio Biotix Therapeutics
Precisio Biotix Therapeutics develops engineered bacteriophage-derived lytic enzymes (lysins) as targeted antimicrobials for chronic and recurrent infections. The company operates a discovery-to-preclinical platform that combines computational design, machine learning, high-throughput expression and automated screening, and advances selected candidates into preclinical and early clinical use via collaborations and expanded-access INDs.
Industries
Nr. of Employees
medium (51-250)
Precisio Biotix Therapeutics
Patents
Disinfection of bacteriophages products using supercritical carbon dioxide
US-12232492-B2
View DetailsComposition comprising amino acid polymers and a bioactive agent and method of preparing thereof
US-11564894-B2
View Details
Disinfection of bacteriophages products using supercritical carbon dioxide
US-12232492-B2
View DetailsComposition comprising amino acid polymers and a bioactive agent and method of preparing thereof
US-11564894-B2
View DetailsProducts
Chimeric anti-staphylococcal lysin (clinical candidate for prosthetic joint infection)
A chimeric lysin engineered to target Staphylococcus spp. for treatment of chronic prosthetic joint infections; advanced to first-in-human use under expanded-access INDs.
Engineered lysin candidates for bacterial vaginosis (preclinical)
Lysins designed to selectively target Gardnerella and associated biofilms to treat or prevent bacterial vaginosis while preserving lactobacilli-dominated microbiota; funded through discovery and preclinical grants.
Engineered lysin programs for respiratory infections (discovery)
Discovery-stage lysin development targeting Gram-positive and Gram-negative pathogens implicated in lower respiratory tract infections, including hospital- and ventilator-associated pneumonia.
Topical lysin-based dermatological products (consumer and therapeutic lines)
Dermatology-focused lysin products for indications such as atopic dermatitis and acne; includes a consumer eczema product with EU market readiness and development-stage therapeutic products.
LysiThru
Machine learning platform to design, engineer, and screen lysins at high throughput.
EczePHx
Lysin-based consumer product for atopic dermatitis and eczema, targeting Staphylococcus aureus.
Chimeric anti-staphylococcal lysin (clinical candidate for prosthetic joint infection)
A chimeric lysin engineered to target Staphylococcus spp. for treatment of chronic prosthetic joint infections; advanced to first-in-human use under expanded-access INDs.
Engineered lysin candidates for bacterial vaginosis (preclinical)
Lysins designed to selectively target Gardnerella and associated biofilms to treat or prevent bacterial vaginosis while preserving lactobacilli-dominated microbiota; funded through discovery and preclinical grants.
Engineered lysin programs for respiratory infections (discovery)
Discovery-stage lysin development targeting Gram-positive and Gram-negative pathogens implicated in lower respiratory tract infections, including hospital- and ventilator-associated pneumonia.
Topical lysin-based dermatological products (consumer and therapeutic lines)
Dermatology-focused lysin products for indications such as atopic dermatitis and acne; includes a consumer eczema product with EU market readiness and development-stage therapeutic products.
LysiThru
Machine learning platform to design, engineer, and screen lysins at high throughput.
EczePHx
Lysin-based consumer product for atopic dermatitis and eczema, targeting Staphylococcus aureus.
Services
Collaborative R&D and co-development agreements with pharmaceutical and strategic partners to advance engineered lysin candidates toward clinical use.
Coordination with clinical centers to enable single-patient expanded-access IND treatments and compassionate use programs for severe infections.
End-to-end discovery using computational design, high-throughput expression and screening to generate and prioritize lysin leads against predefined target profiles.
Collaborative R&D and co-development agreements with pharmaceutical and strategic partners to advance engineered lysin candidates toward clinical use.
Coordination with clinical centers to enable single-patient expanded-access IND treatments and compassionate use programs for severe infections.
End-to-end discovery using computational design, high-throughput expression and screening to generate and prioritize lysin leads against predefined target profiles.
Expertise Areas
- Antimicrobial drug discovery
- Lysin engineering and development
- Machine-learning driven protein design
- High-throughput screening against clinical isolates
Key Technologies
- Machine-learning-driven protein design
- Automated high-throughput expression and screening
- Recombinant protein expression
- Protein structure prediction
News & Updates
First patient dosed with an engineered anti-staphylococcal lysin for a multidrug-resistant prosthetic joint infection under an FDA single-patient expanded-access IND filed by Mayo Clinic.
Peer-reviewed publication detailing a chimeric lysin with therapeutic potential against Staphylococcus aureus in Antimicrobial Agents and Chemotherapy.
Additional expanded-access administration reported for a chronic prosthetic joint infection with no adverse events and a culture-negative joint at one month.
Non-dilutive grant awarded to advance discovery efforts for engineered lysins targeting bacterial vaginosis pathobionts, supporting development toward preclinical testing.
Partnership to advance lysin-based antimicrobials in India, including white paper work and expanded-access programmes.
Publication in Antimicrobial Agents and Chemotherapy describing a chimeric lysin with therapeutic potential for Staphylococcus aureus infections.
First patient dosed with an engineered anti-staphylococcal lysin for a multidrug-resistant prosthetic joint infection under an FDA single-patient expanded-access IND filed by Mayo Clinic.
Peer-reviewed publication detailing a chimeric lysin with therapeutic potential against Staphylococcus aureus in Antimicrobial Agents and Chemotherapy.
Additional expanded-access administration reported for a chronic prosthetic joint infection with no adverse events and a culture-negative joint at one month.
Non-dilutive grant awarded to advance discovery efforts for engineered lysins targeting bacterial vaginosis pathobionts, supporting development toward preclinical testing.
Partnership to advance lysin-based antimicrobials in India, including white paper work and expanded-access programmes.
Publication in Antimicrobial Agents and Chemotherapy describing a chimeric lysin with therapeutic potential for Staphylococcus aureus infections.